TK IMPACT: Treatment Monitoring of Hormone Receptor Positive (HR+), HER2 Negative (HER2-) Metastatic Breast Cancer (MBC) Patients Receiving CDK 4/6 Inhibitors (CDK4/6i) with DiviTum® Thymidine Kinase 1 Activity

被引：1
|
作者：
Bagegni, Nusayba A.
Grigsby, Isabella
Nehring, Leslie
Luo, Jingqin
Carson, Jennifer Powers
Gibson, David W.
Horvath, Meghan
Clifton, Katherine K.
Ademuyiwa, Foluso O.
Suresh, Rama
Frith, Ashley
Davis, Andrew A.
Peterson, Lindsay L.
Bose, Ron
Williams, Amy
Bergqvist, Mattias
Ma, Cynthia
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-11-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
    Lorman-Carbo, Natalia
    Martinez-Saez, Olga
    Fernandez-Martinez, Aranzazu
    Galvan, Patricia
    Chic, Nuria
    Adamo, Barbara
    Vidal, Maria
    Munoz, Montserrat
    Perou, Charles M.
    Gavila, Joaquin
    Pascual, Tomas
    Prat, Aleix
    Braso-Maristany, Fara
    CANCER RESEARCH, 2023, 83 (05)
  • [2] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [3] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Immunologic features and association with prognosis in hormone receptor positive/HER2-negative (HR+/HER2) metastatic breast cancer (MBC) treated with chemotherapy (CT) or CDK4/6-inhibitors (CDK4/6i) + endocrine therapy (ET)
    Schettini, Francesco
    Palleschi, Michela
    Mannozzi, Francesca
    Braso-Maristany, Fara
    Cecconetto, Lorenzo
    Galvan, Patricia
    Mariotti, Marita
    Ferrari, Alessia
    Scarpi, Emanuela
    Miserocchi, Anna
    Nanni, Oriana
    Sanfeliu, Esther
    Prat, Aleix
    Rocca, Andrea
    De Giorgi, Ugo
    CANCER RESEARCH, 2024, 84 (09)
  • [5] Serum thymidine kinase activity as a "real-time" clinical biomarker of tumor response to CDK4/6 inhibition in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer
    Bagegni, Nusayba
    Williams, Amy
    Grigsby, Isabella
    Bergqvist, Mattias
    Clifton, Katherine
    Ma, Cynthia
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
    Boyle, Frances
    Beith, Jane
    Burslem, Katie
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    McCarthy, Nicole
    Redfern, Andrew
    Woodward, Natasha
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 3 - 11
  • [7] A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i)
    Mainor, Candace Bavette
    Barrows, Elizabeth Dominic
    Wang, Hongkun
    Lynce, Filipa
    Ashai, Nadia
    Collins, Julie Marie
    Swanson, Nicole
    Castle, Julie
    Novielli, Antonella
    Slingerland, Joyce
    Isaacs, Claudine
    Pohlmann, Paula R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [9] The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2-metastatic breast cancer (MBC)
    Wander, Seth A.
    Cohen, Ofir
    Gong, Xueqian
    Johnson, Gabriela N.
    Buendia-Buendia, Jorge
    Lloyd, Maxwell
    Kim, Dewey
    Luo, Flora
    Mao, Pingping
    Helvie, Karla
    Kowalski, Kailey
    Nayar, Utthara
    Parsons, Stephen
    Martinez, Ricardo
    Litchfield, Lacey
    Ye, Xiang
    Yu, Chun Ping
    Jansen, Valerie
    Garraway, Levi A.
    Winer, Eric P.
    Tolaney, Sara M.
    Lin, Nancy U.
    Buchanan, Sean
    Wagle, Nikhil
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
12345